 |
 |
 |
Merck 042: Oral HPV Study for HIV-Positive Men
Eligible Candidates:
- HIV-positive men, age 18 or older
- Have CD4+ T cells < 500 within 30 days prior to study entry. If you do not have recent documentation of your T-cell count, we can provide one to you as part of the screening process.
- No change in HIV antiretroviral therapy within 30 days prior to study entry. If you are not currently taking HIV medication, you may also be eligible.
- Additional requirements will be discussed by the study staff
Study Objective:
To compare different ways of testing for oral HPV infection in HIV-positive men.
Study Scheme:
Volunteers complete 3 study visits plus a brief telephone follow up over 20 days. If you have a CD4+ T cell count collected at screening, you will complete 4 study visits. Before entering the study, volunteers will have an oral exam performed by the study doctor or nurse.
On study, volunteers will have oral samples collected using SCOPE® mouthwash and gargle rinse, an oral brush, and a cotton swab. Volunteers will be randomized to complete the oral sample collection methods in different orders. Oral samples will be collected at Day 1, Day 8, and Day 15.
There are no drugs or vaccines used in this study.
For more information, please call 212-263-0362.
Study Drugs: There are no medications in this study.
Study Status: Closed.
Study Staff:
- Michael Marmor, PhD (info)
- Demetre Daskalakis, MD (info)
- Robert Hagerty
- Gary Carlisle, RN
- Richard Hutt, RN
- Richard Silvera
- Dylan Stein
- Alith Maillard
- Sandy Guerrero
- Luis Vargas
Study Sponsors:
- Industry-sponsored Trial (Merck and Co., Inc.)
Study Volunteers Receive:
- Reimbursement for time